Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker JBIO
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Oct 28, 2026 | SCHEDULE 13G | JBIO Jade Biosciences, Inc. | Rupert H. Johnson, Jr. | 0 | 0.0% | SCHEDULE 13G ↗ |
| Oct 28, 2026 | SCHEDULE 13G | JBIO Jade Biosciences, Inc. | Charles B. Johnson | 0 | 0.0% | SCHEDULE 13G ↗ |
| Oct 28, 2026 | SCHEDULE 13G | JBIO Jade Biosciences, Inc. | Franklin Templeton, Inc. | 3.81M | 6.0% | SCHEDULE 13G ↗ |
| Oct 27, 2026 | SCHEDULE 13G | JBIO Jade Biosciences, Inc. | BlackRock, Inc. | 3.32M | 5.2% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | JBIO Jade Biosciences, Inc. | Bong Y. Koh | 5.15M | 8.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | JBIO Jade Biosciences, Inc. | Nimish Shah | 5.15M | 8.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | JBIO Jade Biosciences, Inc. | VHCP Management EG, LLC | 5.15M | 8.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | JBIO Jade Biosciences, Inc. | VHCP Management III, LLC | 5.15M | 8.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | JBIO Jade Biosciences, Inc. | Venrock Healthcare Capital Partners EG, L.P. | 5.15M | 8.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | JBIO Jade Biosciences, Inc. | VHCP Co-Investment Holdings III, LLC | 5.15M | 8.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | JBIO Jade Biosciences, Inc. | Venrock Healthcare Capital Partners III, L.P. | 5.15M | 8.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | JBIO Jade Biosciences, Inc. | Bellevue Asset Management AG | 3.06M | 5.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | JBIO Jade Biosciences, Inc. | Bellevue Group AG | 3.06M | 5.0% | SCHEDULE 13G/A ↗ |
| Jul 17, 2026 | SCHEDULE 13G | JBIO Jade Biosciences, Inc. | Paradigm BioCapital International Fund Ltd. | 2.74M | 4.5% | SCHEDULE 13G ↗ |
| Jul 17, 2026 | SCHEDULE 13G | JBIO Jade Biosciences, Inc. | Senai Asefaw, M.D. | 3.11M | 5.1% | SCHEDULE 13G ↗ |
| Jul 17, 2026 | SCHEDULE 13G | JBIO Jade Biosciences, Inc. | Paradigm BioCapital Advisors GP LLC | 3.11M | 5.1% | SCHEDULE 13G ↗ |
| Jul 17, 2026 | SCHEDULE 13G | JBIO Jade Biosciences, Inc. | Paradigm BioCapital Advisors LP | 3.11M | 5.1% | SCHEDULE 13G ↗ |
| Jul 8, 2026 | SCHEDULE 13G/A (amended) | JBIO Jade Biosciences, Inc. | JANUS HENDERSON GROUP Ltd. | 6.27M | 10.6% | SCHEDULE 13G/A ↗ |
| Jun 9, 2026 | SCHEDULE 13D/A (amended) | JBIO Jade Biosciences, Inc. | Tomas Kiselak | 14.06M | 20.0% | SCHEDULE 13D/A ↗ |
| Jun 9, 2026 | SCHEDULE 13D/A (amended) | JBIO Jade Biosciences, Inc. | Peter Evan Harwin | 14.07M | 20.0% | SCHEDULE 13D/A ↗ |
| Jun 9, 2026 | SCHEDULE 13D/A (amended) | JBIO Jade Biosciences, Inc. | Fairmount Healthcare Co-Invest IV L.P. | 2.66M | 4.4% | SCHEDULE 13D/A ↗ |
| Jun 9, 2026 | SCHEDULE 13D/A (amended) | JBIO Jade Biosciences, Inc. | Fairmount Healthcare Fund II L.P. | 11.41M | 16.2% | SCHEDULE 13D/A ↗ |
| Jun 9, 2026 | SCHEDULE 13D/A (amended) | JBIO Jade Biosciences, Inc. | Fairmount Funds Management LLC | 14.07M | 20.0% | SCHEDULE 13D/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | JBIO Jade Biosciences, Inc. | Janus Henderson Group PLC | 3.11M | 6.3% | SCHEDULE 13G/A ↗ |
| Apr 27, 2026 | SCHEDULE 13G/A (amended) | JBIO Jade Biosciences, Inc. | BlackRock, Inc. | 2.30M | 4.7% | SCHEDULE 13G/A ↗ |
| Mar 5, 2026 | SCHEDULE 13D/A (amended) | JBIO Jade Biosciences, Inc. | Dr. Maha Katabi ("Katabi") | 107,391 | 0.3% | SCHEDULE 13D/A ↗ |
| Mar 5, 2026 | SCHEDULE 13D/A (amended) | JBIO Jade Biosciences, Inc. | Dr. James I. Healy ("Healy") | 107,391 | 0.3% | SCHEDULE 13D/A ↗ |
| Mar 5, 2026 | SCHEDULE 13D/A (amended) | JBIO Jade Biosciences, Inc. | Sofinnova Management X-A, L.L.C. ("SM X LLC") | 107,391 | 0.3% | SCHEDULE 13D/A ↗ |
| Mar 5, 2026 | SCHEDULE 13D/A (amended) | JBIO Jade Biosciences, Inc. | Sofinnova Management X, L.P. ("SM X LP") | 107,391 | 0.3% | SCHEDULE 13D/A ↗ |
| Mar 5, 2026 | SCHEDULE 13D/A (amended) | JBIO Jade Biosciences, Inc. | Sofinnova Venture Partners X, L.P. ("SVP X") | 107,391 | 0.3% | SCHEDULE 13D/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | JBIO Jade Biosciences, Inc. | Bong Y. Koh | 5.12M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | JBIO Jade Biosciences, Inc. | Nimish Shah | 5.12M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | JBIO Jade Biosciences, Inc. | VHCP Management EG, LLC | 5.12M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | JBIO Jade Biosciences, Inc. | VHCP Management III, LLC | 5.12M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | JBIO Jade Biosciences, Inc. | Venrock Healthcare Capital Partners EG, L.P. | 5.12M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | JBIO Jade Biosciences, Inc. | VHCP Co-Investment Holdings III, LLC | 5.12M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | JBIO Jade Biosciences, Inc. | Venrock Healthcare Capital Partners III, L.P. | 5.12M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G | JBIO Jade Biosciences, Inc. | Janus Henderson Group PLC | 3.06M | 6.2% | SCHEDULE 13G ↗ |
| Feb 17, 2026 | SCHEDULE 13G | JBIO Jade Biosciences, Inc. | Bellevue Asset Management AG | 3.34M | 6.8% | SCHEDULE 13G ↗ |
| Feb 17, 2026 | SCHEDULE 13G | JBIO Jade Biosciences, Inc. | Bellevue Group AG | 3.34M | 6.8% | SCHEDULE 13G ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | JBIO Jade Biosciences, Inc. | David Kroin | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | JBIO Jade Biosciences, Inc. | Deep Track Biotechnology Master Fund, Ltd. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | JBIO Jade Biosciences, Inc. | Deep Track Capital, LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Jan 30, 2026 | SCHEDULE 13G/A (amended) | JBIO Jade Biosciences, Inc. | The Vanguard Group | 2.10M | 4.2% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | JBIO Jade Biosciences, Inc. | Patrick J. Heron | 9,488 | 0.0% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | JBIO Jade Biosciences, Inc. | James N. Topper | 9,488 | 0.0% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | JBIO Jade Biosciences, Inc. | Fhmls Xi, L.L.C. | 19,146 | 0.1% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | JBIO Jade Biosciences, Inc. | Fhmls Xi, L.P. | 19,146 | 0.1% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | JBIO Jade Biosciences, Inc. | Frazier Life Sciences XI, L.P. | 19,146 | 0.1% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | JBIO Jade Biosciences, Inc. | Fhmls X, L.L.C. | 9,488 | 0.0% | SCHEDULE 13G/A ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 11:25 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances